Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

9.180 -0.300 (-3.16%)
Streaming Delayed Price Updated: 2:05 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
Expert Ratings For Relay Therapeutics
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
Expert Ratings For Relay Therapeutics
Via Benzinga
Key Takeaways From Relay Therapeutics Analyst Ratings
Via Benzinga
Relay Therapeutics: Q4 Earnings Insights
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
The global 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
Company to disclose new programs from existing unnamed pre-clinical pipeline 
From Relay Therapeutics, Inc.
Via GlobeNewswire
5 Of 7 AI Categories Rose, Slightly,Over Past Week
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 7 AI Categories Declined, On Average, The First Week Of May
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
AI Surge Ending: Only One Category Was Up This Week
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. 
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.